|Videos|January 17, 2023
The Impact of Molecular Alterations in Advanced RAI-R-DTC Treatment Decision-Making
Author(s)Lori J. Wirth, MD
Lori Wirth, MD, explains why the importance of molecular alterations in her treatment decision-making for a patient with advanced RAI-R-DTC, and the other factors she considers for an appropriate treatment.
Advertisement
Advertisement
Related to this article
The designation expands the investigational immunotherapy’s development across tumor types for patients whose disease progresses after prior treatment, including immune checkpoint inhibition.
The phase 2/3 AHEAD-MERIT trial will continue to evaluate patients with HPV-positive head and neck squamous cell carcinoma for its second primary end point of overall survival.
Advertisement
Advertisement